Failure of ovarian ablation with goserelin in a pre-menopausal breast cancer patient resulting in pregnancy: a case report and review of the literature

By Hill N.   Madarnas Y.  

Breast Cancer Research and Treatment, Vol. 129, Iss. 1, 2011-08 ,pp. : 265-268

Springer Publishing Company

Access to resources Recommend Favorite

Survival analyses from the ZEBRA study - goserelin (Zoladex(TM)) versus CMF in premenopausal women with node-positive breast cancer

By Kaufmann M.   Jonat W.   Blamey R.   Cuzick J.   Namer M.   Fogelman I.   de Haes J.C.   Schumacher M.   Sauerbrei W.   on behalf of the Zoladex Early Breast Cancer Research Association ZEBRA Trialists' Group  

European Journal of Cancer, Vol. 39, Iss. 12, 2003-08 ,pp. : 1711-1717

Elsevier

Access to resources Recommend Favorite

Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrinedependent breast cancer: A report of two cases

By          

Oncology Letters, Vol. 8, Iss. 3, 2014-01 ,pp. : 1279-1282

Spandidos Publications

Access to resources Recommend Favorite

An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer

By Crump M.  

Breast Cancer Research and Treatment, Vol. 44, Iss. 3, 1997-07 ,pp. : 201-210

Springer Publishing Company

Access to resources Recommend Favorite

A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1

By Sawka C.A.  

Breast Cancer Research and Treatment, Vol. 44, Iss. 3, 1997-07 ,pp. : 211-215

Springer Publishing Company

Access to resources Recommend Favorite